Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Ultragenyx Pharmaceutical Inc. (RARE)

Compare
33.84
-2.37
(-6.55%)
At close: April 1 at 4:00:00 PM EDT
34.29
+0.45
+(1.33%)
Pre-Market: 4:02:28 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
560,230
560,230
434,249
363,329
351,406
Cost of Revenue
76,728
76,728
45,209
28,320
16,008
Gross Profit
483,502
483,502
389,040
335,009
335,398
Operating Expense
1,019,475
1,019,475
958,248
983,928
717,135
Operating Income
-535,973
-535,973
-569,208
-648,919
-381,737
Net Non Operating Interest Income Expense
-26,535
-26,535
-39,316
-31,941
-27,494
Other Income Expense
-5,078
-5,078
60
-20,865
-43,750
Pretax Income
-567,586
-567,586
-608,464
-701,725
-452,981
Tax Provision
1,597
1,597
-1,825
5,696
1,044
Net Income Common Stockholders
-569,183
-569,183
-606,639
-707,421
-454,025
Diluted NI Available to Com Stockholders
-569,183
-569,183
-606,639
-707,421
-454,025
Basic EPS
-6.29
-6.29
-8.25
-10.12
-6.70
Diluted EPS
-6.29
-6.29
-8.25
-10.12
-6.70
Basic Average Shares
90,538.12
90,538.12
73,543.86
69,914.23
67,795.54
Diluted Average Shares
90,538.12
90,538.12
73,543.86
69,914.23
67,795.54
Total Operating Income as Reported
-535,973
-535,973
-569,208
-648,919
-381,737
Total Expenses
1,096,203
1,096,203
1,003,457
1,012,248
733,143
Net Income from Continuing & Discontinued Operation
-569,183
-569,183
-606,639
-707,421
-454,025
Normalized Income
-568,302.15
-568,302.15
-607,034.81
-692,174.79
-423,319.01
Interest Income
36,506
36,506
26,688
11,074
1,928
Interest Expense
63,041
63,041
66,004
43,015
29,422
Net Interest Income
-26,535
-26,535
-39,316
-31,941
-27,494
EBIT
-504,545
-504,545
-542,460
-658,710
-423,559
EBITDA
-469,002
-469,002
-516,454
-640,490
-410,320
Reconciled Cost of Revenue
76,728
76,728
45,209
28,320
16,008
Reconciled Depreciation
35,543
35,543
26,006
18,220
13,239
Net Income from Continuing Operation Net Minority Interest
-569,183
-569,183
-606,639
-707,421
-454,025
Total Unusual Items Excluding Goodwill
-1,115
-1,115
397
-19,299
-42,063
Total Unusual Items
-1,115
-1,115
397
-19,299
-42,063
Normalized EBITDA
-467,887
-467,887
-516,851
-621,191
-368,257
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-234.15
-234.15
1.19
-4,052.79
-11,357.01
12/31/2021 - 1/31/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AGIO Agios Pharmaceuticals, Inc.
27.40
-6.48%
 
CRNX Crinetics Pharmaceuticals, Inc.
30.62
-8.71%
 
PTCT PTC Therapeutics, Inc.
46.60
-8.56%
 
SWTX SpringWorks Therapeutics, Inc.
41.88
-5.10%
 
RYTM Rhythm Pharmaceuticals, Inc.
50.00
-5.61%
 
MREO Mereo BioPharma Group plc
2.1700
-3.56%
 
NUVL Nuvalent, Inc.
68.00
-4.12%
 
CYTK Cytokinetics, Incorporated
37.50
-6.69%
 
RNA Avidity Biosciences, Inc.
26.74
-9.42%
 
ASND Ascendis Pharma A/S
151.43
-2.84%